Try GOLD - Free
"When domestic and global players stand together, it strengthens the entire diagnostics ecosystem"
Bio Spectrum
|November 2025
The Association of Diagnostics Manufacturers of India (ADMI), the apex body representing the country's in vitro diagnostics (IVD) industry, has announced the election of Jatin Mahajan, Managing Director of J. Mitra & Co., as its new President recently. In an interaction with BioSpectrum India Mahajan explains how ADMI can create inclusive working groups and open forums within the association, allowing MNCs and Indian firms to share perspectives and align on goals. Edited excerpts:
Being the newly appointed president of the ADMI, how do you foresee the future of India's diagnostic sector?
I am optimistic about the future of India’s diagnostic sector. We're at a juncture where diagnostics are rightly being recognised as a cornerstone of healthcare. In the coming years, I see India becoming a global hub for affordable, high-quality diagnostics. Our industry is growing at a double-digit rate, and I anticipate that momentum will continue. More Indian companies will move up the value chain - not just making basic kits, but developing sophisticated molecular diagnostics, AI-driven testing tools, and even exporting lab automation systems. The Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) will catalyse increased spending on R&D, and we anticipate the resultant positive outcomes in the years to come. With initiatives like the PLI scheme creating “global champion” IVD firms out of India, we will have a stronger manufacturing base & innovation pipeline.
Domestically, diagnostics will penetrate deeper: I expect a laboratory or point-of-care facility in every small town, enabled by cost-effective tech developed here. From a global perspective, India’s reputation as an exporter of reliable diagnostic products will be solidified - we're already seeing our export growth outpace imports. This trend should enable us to become net exporters by the end of the decade. As ADMI President, I plan to push for all the necessary enablers to realise this vision. The future is one where Indian-developed diagnostic tests and devices are used worldwide, and every citizen has access to timely and accurate tests at home. In short, the outlook is of robust growth and innovation, with India's diagnostics sector attaining a position of global leadership while saving millions of lives through early and precise disease detection.
How big and diverse is the IVD market in India?
This story is from the November 2025 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum
Bio Spectrum
MAHE teams up with OpenAI to integrate AI to enhance outcomes
Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.
1 min
April 2026
Bio Spectrum
Jubilant Bhartia Foundation & McGill University to launch CoE in AI education
The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research.
1 min
April 2026
Bio Spectrum
Heeding Auditory Warning Signs
By 2050, nearly 2.5 billion people are projected to have some degree of hearing loss, and more than 700 million might require hearing rehabilitation. That's according to the World Health Organization (WHO).
2 mins
April 2026
Bio Spectrum
Botanic Healthcare on-boards Narahari Naidu as Group Chief Financial Officer
Secundarabad-based Botanic Healthcare, a globally leading nutraceutical company, has announced the appointment of Narahari Naidu as its Group Chief Financial Officer (CFO).
1 min
April 2026
Bio Spectrum
Paras Health ropes in Balkishan Sharma as Group CHRO and Business Transformation Officer
Paras Health has announced the appointment of Balkishan Sharma as Group Chief Human Resources Officer (Group CHRO) and Business Transformation Officer.
1 min
April 2026
Bio Spectrum
Parse Biosciences unveils Evercode Whole Transcriptome V4 with shorter workflow
Parse Biosciences, a Qiagen company, has announced the launch of the new Evercode Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers
1 min
April 2026
Bio Spectrum
UK deploys new bone scanners to help prevent fractures
Tens of thousands of patients at risk of osteoporosis and other bone conditions will get faster access to vital bone scans, as 20 new scanners are rolled out across England.
1 min
April 2026
Bio Spectrum
Cytiva expands Fast Trak process development and validation services facility in India
Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.
1 min
April 2026
Bio Spectrum
ΑΙ TAKES INDIAN PHARMA REINS
The Indian pharmaceutical sector, one of the largest in the world, is undergoing a strategic transformation in the way it operates. As artificial intelligence (AI) gains prominence across the industry, companies are actively adopting Al-driven solutions to enhance efficiency across the entire pharmaceutical ecosystem. Organisations are investing in AI training programmes to keep their workforce future-ready, foster innovation, strengthen supply chains, and transition away from manual record-keeping. In this industry analysis, experts share their perspectives on how AI is shaping the future of the pharma sector.
10 mins
April 2026
Bio Spectrum
NIH halts arm of clinical trial evaluating potential stroke treatment
The National Institutes of Health (NIH) in the US has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) study, following a regular review by the Data Safety and Monitoring Board (DSMB).
1 min
April 2026
Listen
Translate
Change font size
